L&K Biomed Selected as the Best Partner for Technology Commercialization

Award of Appreciation Received by Bundang Seoul National University Hospital

Spine manufacturing specialist L&K Biomed announced on the 12th that it was selected as the Best Technology Commercialization Partner of the Year at the '2024 Healthcare Innovation Park Research Fair' and received a plaque of appreciation from Bundang Seoul National University Hospital.

Hosted by Bundang Seoul National University Hospital, the '2024 Healthcare Innovation Park Research Fair' was held on the 11th at the Future Hall on the 4th floor of the Healthcare Innovation Park at Bundang Seoul National University Hospital in Bundang-gu, Seongnam-si, Gyeonggi-do. The event aims to strengthen research capabilities by expanding exchanges among researchers in the healthcare field and promoting joint research with companies. About 170 industry-academia-research stakeholders attended, including Song Jeong-han, Director of Bundang Seoul National University Hospital, Lee Hak-jong, Director of the Medical and Life Sciences Research Institute, and Seo Jang-won, Head of the Finance Team at L&K Biomed’s Management Support Division.

Since establishing L&K Biomed in 2008, the company developed Korea’s first next-generation height-expandable spinal implant technology. While proceeding with domestic and international patent applications and registrations, it was recognized for its contribution to revitalizing the healthcare industry and technology commercialization through continuous investment and research efforts in developing next-generation spinal implant technology, earning the plaque of appreciation.

In addition, the event featured ▲ performance cases from Seoul National University Hospital’s Medical and Life Sciences Research Institute ▲ performance cases from Seoul National University’s Innovative Future Medical Research Center ▲ technology commercialization and startup success cases ▲ and an idea contest.

A representative from L&K Biomed stated, "Through continuous research and innovative technology development, we have recently strengthened product competitiveness by obtaining FDA approval in the United States for six new BlueX series products." They added, "We have successfully entered new markets such as Southeast Asia and Central Asia." Furthermore, they said, "By making a new leap forward as a global total healthcare group that contributes to the healthy lives of humanity, we will further contribute to technology commercialization in the healthcare field."

This content was produced with the assistance of AI translation services.